外科理论与实践 ›› 2024, Vol. 29 ›› Issue (01): 1-4.doi: 10.16139/j.1007-9610.2024.01.01
• 专家论坛 • 下一篇
收稿日期:
2023-11-30
出版日期:
2024-01-25
发布日期:
2024-05-14
通讯作者:
张太平
E-mail:tpingzhang@yahoo.com
基金资助:
ZHANG Taiping(), WENG Guihu, LIU Yueze
Received:
2023-11-30
Online:
2024-01-25
Published:
2024-05-14
Contact:
ZHANG Taiping
E-mail:tpingzhang@yahoo.com
摘要:
作为一种系统性疾病,胰腺癌恶性程度高,复发转移率高,诊治与管理尤为困难。近年来随着新辅助治疗理念的不断推广,胰腺癌的治疗愈发强调在全流程、多方位管理中制定综合性、个性化治疗方案。然而,目前针对新辅助治疗在可切除胰腺癌中的应用尚存诸多争议。本文拟结合国、内外指南及最新研究进展,针对可切除胰腺癌病人实施新辅助治疗中的热点话题及相关争议进行探讨,以期推动新辅助治疗在可切除胰腺癌中的规范化应用。
中图分类号:
张太平, 翁桂湖, 刘悦泽. 可切除胰腺癌新辅助治疗的研究及指南解读,肯定还是否定?[J]. 外科理论与实践, 2024, 29(01): 1-4.
ZHANG Taiping, WENG Guihu, LIU Yueze. Research and guidelines interpretation of neoadjuvant therapy for resectable pancreatic cancer, promising or limited?[J]. Journal of Surgery Concepts & Practice, 2024, 29(01): 1-4.
[1] |
SPRINGFELD C, FERRONE C R, KATZ M H G, et al. Neoadjuvant therapy for pancreatic cancer[J]. Nat Rev Clin Oncol, 2023, 20(5):318-337.
doi: 10.1038/s41571-023-00746-1 pmid: 36932224 |
[2] | 孟令威, 吴仲, 彭兵. 胰腺癌新辅助化疗后的微创治疗[J]. 中国普外基础与临床杂志, 2023, 30(9):1025-1029. |
MENG L W, WU Z, PENG B. Minimally invasive treatment of pancreatic cancer after neoadjuvant chemotherapy[J]. Chin J Bases Clin Gen Surg, 2023, 30(9):1025-1029 | |
[3] | VERSTEIJNE E, VAN DAM J L, SUKER M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial[J]. J Clin Oncol, 2022, 40(11):1220-1230. |
[4] | SEUFFERLEIN T, UHL W, KORNMANN M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX) — a randomized phase Ⅱ trial of the AIO pancreatic cancer group[J]. Ann Oncol, 2023, 34(1):91-100. |
[5] |
SOHAL D P S, DUONG M, AHMAD S A, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial[J]. JAMA Oncol, 2021, 7(3):421-427.
doi: 10.1001/jamaoncol.2020.7328 pmid: 33475684 |
[6] | USON JUNIOR P L S, DIAS E SILVA D, DE CASTRO N M, et al. Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials[J]. ESMO Open, 2023, 8(1):100771. |
[7] | 杨尹默, 田孝东. 中国胰腺癌诊治指南(2021)[J]. 中国实用外科杂志, 2021, 41(7):725-738. |
YANG Y M, TIAN X D. Chinese guidelines for diagnosis and treatment of pancreatic cancer(2021)[J]. Chin J Pract Surg, 2021, 41(7):725-738. | |
[8] | TEMPERO M A, MALAFA M P, AL-HAWARY M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(4):439-457. |
[9] | WU V S, ELSHAMI M, STITZEL H J, et al. Why the treatment sequence matters: interplay between chemotherapy cycles received, cumulative dose intensity, and survival in resected early-stage pancreas cancer[J]. Ann Surg, 2023, 278(4):e677-e684. |
[10] | ZOU Y, GAO S, YU X, et al. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage Ⅰ-Ⅲ pancreatic ductal adenocarcinoma: a retrospective cohort study[J]. Int J Surg, 2023, 109(6):1573-1583. |
[11] | STRICKLER J H, SATAKE H, GEORGE T J, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer[J]. N Engl J Med, 2023, 388(1):33-43. |
[12] | BEKAII-SAAB T S, YAEGER R, SPIRA A I, et al. Adagrasib in advanced solid tumors harboring a KRASG12C mutation[J]. J Clin Oncol, 2023, 41(25):4097-4106. |
[13] |
KING D, KAMRAN U, DOSANJH A, et al. Rate of pancreatic cancer following a negative endoscopic ultrasound and associated factors[J]. Endoscopy, 2022, 54(11):1053-1061.
doi: 10.1055/a-1784-1661 pmid: 35359019 |
[14] | SAGAMI R, NAKAHODO J, MINAMI R, et al. True diagnostic ability of EUS-guided fine-needle aspiration/biopsy sampling for small pancreatic lesions ≤10 mm and salvage diagnosis by pancreatic juice cytology: a multicenter study[J]. Gastrointest Endosc, 2024, 99(1):73-80. |
[15] | VAN EIJCK C W F, MUSTAFA D A M, VADGAMA D, et al. Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer[J]. Gut, 2024, 73(2):311-324. |
[16] | NAKAJIMA K, INO Y, NAITO C, et al. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5[J]. Br J Cancer, 2022, 126(4):628-639. |
[17] |
BYRNE K T, BETTS C B, Mick R, et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer[J]. Clin Cancer Res, 2021, 27(16):4574-4586.
doi: 10.1158/1078-0432.CCR-21-1047 pmid: 34112709 |
[18] | REDEGALLI M, GRASSINI G, MAGLIACANE G, et al. Routine molecular profiling in both resectable and unresectable pancreatic adenocarcinoma: relevance of cytologic samples[J]. Clin Gastroenterol Hepatol, 2023, 21(11):2825-2833. |
[19] | ECKER B L, TAO A J, JANSSEN Q P, et al. Genomic biomarkers associated with response to induction chemotherapy in patients with localized pancreatic ductal adenocarcinoma[J]. Clin Cancer Res, 2023, 29(7):1368-1374. |
[20] | ZHOU X, AN J, KURILOV R, et al. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC[J]. Nat Cancer, 2023, 4(9):1362-1381. |
[1] | 王美文, 傅宁稹, 王伟珅, 任新平. 胰十二指肠联合静脉切除重建术后早期血管栓塞的床旁超声诊断及危险因素分析[J]. 外科理论与实践, 2024, 29(01): 54-60. |
[2] | 高卫奇, 张旭, 王铮, 朱一霏, 黄佳慧, 洪进, 朱思吉, 陈小松, 黄欧, 何建蓉, 陈伟国, 李亚芬, 沈坤炜, 徐华, 吴佳毅. 新辅助治疗后腹壁下深血管穿支皮瓣即刻乳房重建手术的安全性研究[J]. 外科理论与实践, 2023, 28(02): 147-151. |
[3] | 邢颖, 程石. 胆囊癌新辅助治疗的现状和争议[J]. 外科理论与实践, 2023, 28(02): 110-114. |
[4] | 张吉祥, 谢智华, 综述, 李炜, 姜小清, 审校. 肝内胆管癌的分型和外科治疗热点[J]. 外科理论与实践, 2022, 27(05): 478-482. |
[5] | 陈小松, 沈坤炜, 李宏为. 早期可手术乳腺癌的诊治现状与展望[J]. 外科理论与实践, 2022, 27(05): 385-386. |
[6] | 郭杨, 郭天安, 徐烨. 直肠癌新辅助化疗的研究进展[J]. 外科理论与实践, 2022, 27(04): 370-374. |
[7] | 许梓枫 综述, 宗雅萍, 陆爱国 审校. 局部进展期结肠癌病人的新辅助治疗[J]. 外科理论与实践, 2022, 27(03): 266-270. |
[8] | 何敏, 刘颖斌. 可切除胰腺癌的判断标准与治疗及其争议[J]. 外科理论与实践, 2022, 27(01): 6-10. |
[9] | 黄乃思, 陈嘉莹, 嵇庆海, 王宇. 靶向药物时代局部晚期甲状腺癌的新辅助治疗[J]. 外科理论与实践, 2021, 26(06): 493-496. |
[10] | 蔡晨, 龚伟. 胆囊癌辅助治疗的研究进展[J]. 外科理论与实践, 2021, 26(02): 167-170. |
[11] | 陈祥锦, 朱有志. 乳腺癌新辅助治疗后的外科处理[J]. 外科理论与实践, 2019, 24(05): 388-390. |
[12] | 陈献则, 程兮, 吴浩旋, 张弢, 季晓频, 赵任. 高通量转录组测序初步研究结肠直肠癌新辅助治疗敏感性[J]. 外科理论与实践, 2018, 23(01): 67-71. |
[13] | 韩俊毅, 傅传刚,. 中低位直肠癌个体化新辅助放、化疗[J]. 外科理论与实践, 2016, 21(06): 464-467. |
[14] | 宗瑜, 吴佳毅, 陈伟国,. 乳腺癌新辅助治疗后的外科治疗[J]. 外科理论与实践, 2016, 21(04): 356-360. |
[15] | 朱丽, 高卫奇,. 乳腺癌分子分型时代的新辅助治疗[J]. 外科理论与实践, 2014, 19(05): 385-388. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||